Streetbeat News

Products Services

INM

InMed Pharmaceuticals announced Phase 2 trial results for its INM-755 CBN cream, stating that the results for non-wound itch were not statistically significant due to the anti-itch effect of the control cream.

Portfolio Pulse from Bill Haddad

June 22, 2023 | 11:37 am

ROIV

Roivant reports positive long-duration data for RVT-3101 from TUSCANY-2 Phase 2b study in ulcerative colitis, showing improved clinical remission and endoscopic improvement. The treatment was well tolerated and had a favorable safety profile.

Portfolio Pulse from Bill Haddad

June 22, 2023 | 11:36 am

ALZN

Alzamend Neuro plans to conduct two Phase II clinical trials to investigate the safety and efficacy of AL001 for patients with mild to moderate Alzheimer's disease.

Portfolio Pulse from Benzinga Newsdesk

June 22, 2023 | 11:31 am

ALZN

Alzamend Neuro revealed that their lithium dose, equivalent to 240 mg of lithium carbonate taken 3 times daily, is designed to not require therapeutic drug monitoring.

Portfolio Pulse from Benzinga Newsdesk

June 22, 2023 | 11:31 am

ALZN

Alzamend Neuro has identified a maximum tolerated dose for the development of AL001 from a multiple-ascending dose study, as assessed by an independent safety review committee.

Portfolio Pulse from Benzinga Newsdesk

June 22, 2023 | 11:30 am

ALZN

Alzamend Neuro has identified a maximum tolerated dose (MTD) for developing AL001 from a multiple-ascending dose study. The company expects to initiate two AL001 Phase 2 trials for patients with mild to moderate Alzheimer's in Q1 of 2024 and submit FDA investigational new drug applications by the end of 2023.

Portfolio Pulse from Vandana Singh

June 22, 2023 | 11:30 am

RNLSY

Renault SA plans to build electric vehicle (EV) infrastructure in Busan, South Korea, with an aim to produce 200,000 EVs annually at its Busan facilities. The investment range for the plant has not been disclosed.

Portfolio Pulse from Shivani Kumaresan

June 22, 2023 | 11:25 am

RNAZ

TransCode Therapeutics announced the publication of new data supporting the use of TTX-MC138 for the treatment of metastatic breast cancer. The data suggests that TTX-MC138 has the potential to improve patient outcomes.

Portfolio Pulse from Bill Haddad

June 22, 2023 | 11:08 am

PYPD

PolyPid has announced the recruitment of the first patient in its revised SHIELD II Phase 3 trial, which evaluates D-PLEX₁₀₀ for the prevention of abdominal colorectal surgical site infections.

Portfolio Pulse from Bill Haddad

June 22, 2023 | 11:07 am

GMAB

Genmab announced that Epcoritamab has been added to the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology for B-Cell Lymphomas. This inclusion may positively impact the company's reputation and stock.

Portfolio Pulse from Bill Haddad

June 22, 2023 | 11:05 am